Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Dispensing Fee Revision to Hit Major Dispensing Pharmacies: JPA
April 3, 2006
- Japan Should Participate in Global Trials from an Early Stage: Mr Mori of PMDA
April 3, 2006
- JPA's Top Priority Projects Outlined by Mr Ishii
April 3, 2006
- R&D NEWS IN BRIEF
April 3, 2006
- Hodanren Submits Petition on NHI Pricing, Medical Fees
April 3, 2006
- SEMINAR
April 3, 2006
- Meeting of Prefectural Pharm. Affairs Managers
April 3, 2006
- TeGenero's Investigational Antibody Drug Causes Disaster in PI Trial
April 3, 2006
- The WHO, IFPMA to Cooperate to Combat Counterfeit Drugs
April 3, 2006
- Korosho to Standardize Package Inserts for Generics
April 3, 2006
- REGULATORY NEWS IN BRIEF
April 3, 2006
- Shift to Low-priced Drugs Could Weaken Wholesalers: FJPWA
April 3, 2006
- SELF-MEDICATION NEWS IN BRIEF
April 3, 2006
- HUMAN RESOURCES NEWS IN BRIEF
April 3, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 3, 2006
- STATISTICS
April 3, 2006
- MEDICAL DEVICE NEWS IN BRIEF
April 3, 2006
- Takeda to Emphasize Concept-based R&D Model
April 3, 2006
- SURVEY 2 articles
April 3, 2006
- BUSINESS NEWS IN BRIEF
March 27, 2006
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…